Table 9. The changes in the estimated glomerular filtration rate and the number of events in the patients with or without renal biopsy, classified by the plasma levels of vasohibin-1.
Baseline | One year | Two years | Three years | Number of events | ||||||
n | eGFR | n | eGFR | n | eGFR | n | eGFR | Total | RRT or Death | |
The plasma levels of VASH-1 in patients with RB | ||||||||||
Low (<609 fmol/mL) | 23 | 67±28 | 10 | 80±22 | 8 | 73±19 | 6 | 70±26 | 0 | 0 |
High (≥609 fmol/mL) | 22 | 84±27a | 14 | 69±25 | 11 | 70±24 | 9 | 73±22 | 3 | 1 |
The plasma levels of VASH-1 in patients without RB | ||||||||||
Low (<609 fmol/mL) | 10 | 36±26 | 6 | 43±28 | 4 | 51±26 | 5 | 51±32 | 2 | 2 |
High (≥609 fmol/mL) | 12 | 20±18 | 7 | 22±9 | 7 | 19±13 | 5 | 20±13 | 8a | 5 |
Abbreviations: eGFR, estimated glomerular filtration rate (mL/min/1.73 m2); RB, renal biopsy; RRT, renal replacement therapy; VASH-1, vasohibin-1. A composite renal event was defined as a decline in the eGFR of more than 30% of the baseline value, initiation of RRT or death associated with a renal disorder. The values are expressed as the means ± SD. The average eGFR did not include the values from the patients who received RRT or died.
P<0.05 versus the Low group.